Market Overview
The Australia age-related macular degeneration market reached USD 209.12 Million in 2025 and is expected to grow to USD 239.47 Million by 2034. This reflects a growth rate of 1.52% over the forecast period 2026-2034. Market expansion is supported by Australia’s aging population, enhanced government healthcare policies, and the integration of artificial intelligence in early diagnosis and disease monitoring. For detailed insights, see the Australia Age-Related Macular Degeneration Market.
How AI is Reshaping the Future of Australia Age-Related Macular Degeneration Market:
- Advanced AI deep learning algorithms analyze optical coherence tomography scans and color fundus photographs with accuracy comparable or superior to human experts.
- AI models predict disease progression and optimize anti-VEGF injection intervals, enabling personalized treatment regimens.
- Remote AI-enabled screening addresses geographic healthcare disparities by facilitating early detection and monitoring in rural and remote areas.
- Telemedicine platforms incorporating AI diagnostic support allow preliminary AMD screening in primary care settings for timely referrals.
- A qualitative study by UNSW Sydney involving 37 stakeholders highlighted growing acceptance of AI-driven diagnostics in Australian clinical practice.
- Despite rapid technological adoption, careful integration of AI requires algorithm validation, transparent communication, human oversight, and robust data governance to ensure fairness and privacy.
Grab a sample PDF of this report: https://www.imarcgroup.com/australia-age-related-macular-degeneration-market/requestsample
Market Growth Factors
Australia’s rapidly aging population is a major driver of the age-related macular degeneration (AMD) market. AMD is the leading cause of blindness among Australians aged over 50, currently affecting approximately 1.25 million people nationally. This number is projected to rise, intensifying demand for diagnostic services, anti-VEGF therapies, and ophthalmologic care. Demographic data from the Australian Bureau of Statistics indicates that by 2066, nearly one in four Australians will be over 65, expanding the at-risk group significantly. The aging population drives increased healthcare expenditure and necessitates expanded specialist capacity and innovative service delivery models in both metropolitan and regional areas.
Government policy initiatives significantly boost market growth through enhanced treatment accessibility and affordability. The National Strategic Action Plan for Macular Disease launched in 2022 coordinates national efforts to improve macular disease services, research funding, and patient support. The Pharmaceutical Benefits Scheme subsidizes anti-VEGF medications like Lucentis, Eylea, Beovu, and Vabysmo, reducing out-of-pocket costs. State and territory collaborations focus on expanding public hospital eye injection clinics to meet demand while upholding treatment quality, reflecting political commitment to addressing AMD as a national health priority.
Artificial intelligence is transforming AMD diagnosis, monitoring, and treatment optimization in Australia. AI systems demonstrate diagnostic accuracy competitive with experienced retinal specialists and enable prediction of disease progression and optimization of treatment intervals. AI-enabled remote screening and telemedicine platforms address Australia’s geographic challenges by expanding access to quality eye care, particularly in rural and remote populations. The adoption of AI-driven tools is growing in clinical practice, supported by studies showing stakeholder acceptance. Strategic integration of AI improves resource allocation and patient outcomes, although it requires careful validation and oversight.
Market Segmentation
Analysis by Product:
- Eylea
- Lucentis
- Beovu
- Others
Analysis by Disease Type:
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
Analysis by Region:
- Australia Capital Territory & New South Wales
- Victoria & Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Key Players
- BenoBio
Recent Developement & News
- July 2025: The Australian government expanded the National Strategic Action Plan for Macular Disease, enhancing early detection capabilities and treatment accessibility, particularly across underserved regional and rural areas, thereby improving service equity.
- August 2025: BenoBio initiated a Phase 2 clinical trial for BBRP11001, an experimental small-molecule inhibitor for neovascular AMD patients resistant to conventional anti-VEGF therapies, highlighting innovation focused on unmet clinical needs.
- October 2025: New approvals by Australia’s Therapeutic Goods Administration for SYFOVRE and IZERVAY provide treatment options for geographic atrophy in dry AMD, marking significant progress in addressing a long-standing unmet medical need.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=44015&flag=C
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201-971-6302
Recent Comments